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Abstract
Background: The 15q25.1 lung cancer susceptibility locus, containing CHRNA5, could modify lung cancer susceptibility and
multiple smoking related phenotypes. However, no studies have investigated the association between CHRNA5 rs3841324,
which has been proven to have the highest association with CHRNA5 mRNA expression, and the risk of other smoking-
associated cancers, except lung cancer. In the current study we examined the association between rs3841324 and
susceptibility to smoking-associated nasopharyngeal carcinoma (NPC).
Methods: In this case-control study we genotyped the CHRNA5 rs3841324 polymorphism with 400 NPC cases and 491
healthy controls who were Han Chinese and frequency-matched by age (65 years), gender, and alcohol consumption.
Univariate and multivariate logistic regression analyses were used to calculate the odds ratio (OR) and 95% confidence
intervals (95% CI).
Results: We found that individuals with CHRNA5 rs3841324 combined variant genotypes (ins/del+del/del) had a .1.5-fold
elevated risk for NPC than those with the ins/ins genotype (adjusted OR = 1.52; 95% CI, 1.16–2.00), especially among ever
smokers (adjusted OR = 2.07; 95% CI, 1.23–3.48). The combined variant genotypes acted jointly with cigarette smoking to
contribute to a 4.35-fold increased NPC risk (adjusted OR = 4.35; 95% CI, 2.57–7.38). There was a dose-response relationship
between deletion alleles and NPC susceptibility (trend test, P = 0.011).
Conclusions: Our results suggest that genetic variants on the 15q25.1 lung cancer susceptibility locus may influence
susceptibility to NPC, particularly for smoking-associated NPC. Such work may be helpful to facilitate an understanding of
the etiology of smoking-associated cancers and improve prevention efforts.
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Introduction
Cigarette smoking is a major public health problem, accounting
for 5 million deaths annually worldwide [1], and contributing to
31% and 6% of all cancer deaths in men and women worldwide
for people between 30 and 69 years of age, respectively [2].
Nicotine, a component of cigarettes, can promote cancer cell
proliferation, survival, migration, invasion, etiology, and develop-
ment [3], Nicotine has been shown to be involved with the
pathogenesis of many cancers, including nasopharyngeal carcino-
ma (NPC) [4]; however, there is no evidence that the carcinogenic
mechanisms associated with nicotine and genetic variants influ-
ence susceptibility to NPC.
Genome-wide association studies (GWAS) have identified that
chromosome 15q25.1, composed of nicotinic acetylcholine recep-
tor genes, including CHRNA5 and CHRNA3, are lung cancer
susceptibility regions [5,6] and play a potential role in multiple
smoking-related phenotypes and nicotine dependence [7].
CHRNA5, a member of the ligand-gated ion channels, modulates
cell membrane potentials and physiologic processes, including
neurotransmission [8] and cancer signaling [9]. Tobacco alkaloid
and nicotine can bind and activate nicotinic acetylcholine
receptors and thereby stimulate cellular proliferation and tumor
invasion, and inhibit apoptosis [9–11]. Although it has been
reported that nicotine-mediated activation of CHRNA3 and
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CHRNA5 can influence lung cancer risk directly, it also has been
suggested that the 15q25.1 lung cancer susceptibility locus
influences lung cancer risk at least in part through an effect on
smoking persistence [12] because the variants at 15q25.1 are also
associated with smoking behavior and nicotine dependence [13].
Therefore, variants at 15q25.1 might affect other smoking-
associated cancers than lung cancer. However, there is only one
study that has examined the association between genetic variants
at the 15q25.1 lung cancer susceptibility locus (rs8034191 and
rs1051730) and the risk of another smoking-associated cancer
other than lung cancer (pancreatic cancer) and found no
significant association [14]. Therefore, it is unclear whether or
not the 15q25.1 lung cancer susceptibility locus is confined to the
lung or influences cancer susceptibility related to carcinogenic
compound exposure in cigarette smoking.
CHRNA5 rs3841324, a 22 bp insertion (ins)/deletion (del) at
position 271 upstream of the transcription start site, has been
shown to have the greatest association with CHRNA5 mRNA
levels in lung tissue [15], and accounts for approximately 42% of
the alteration in CHRNA5 mRNA expression [15]. However,
compared to the CHRNA5 rs3841324 ins/ins and ins/del
genotypes, the del/del genotype show inconsistent transcription
level in different populations. In European descent, the del/del
genotype has a 2.9-fold increase in CHRNA5 mRNA levels [15]
and significantly reduces the lung cancer risk in female Caucasian
ever-smokers [6], while in Han Chinese the del/del genotype is
associated with hypoactivity of the promoter and decreased
transcription [16]. On the other hand, only the CHRNA5
rs3841324 SNP has been investigated with respect to the possible
relationship with lung cancer susceptibility. Therefore, there is an
urgent need to investigate whether or not CHRNA5 rs3841324 is
involved in susceptibility to smoking-associated cancers in addition
to lung cancer.
Our previous large epidemiologic study showed that cigarette
smoking is a significant risk factor for NPC [4], which is consistent
with previous findings [17,18]. Thus, to determine whether or not
genetic variations in the 15q25.1 lung cancer susceptibility locus
are implicated in the carcinogenesis of cigarette smoking-mediated
cancer risk other than lung cancer, we evaluated the association
between the CHRNA5 rs3841324 polymorphism and NPC risk in
general and in subgroups of subjects stratified by age, gender,
cigarette smoking, alcohol consumption, and pathology, and
explored the joint effect between CHRNA5 rs3841324 and
cigarette smoke exposure on NPC risk with 400 patients newly
diagnosed with NPC and 491 cancer-free healthy controls. Such
work may help facilitate an understanding of the carcinogenic
mechanisms by which genetic variants at these regions influence




Four hundred newly diagnosed patients, previously untreated
with histopathologically-confirmed NPC without age, gender, and
cancer stage or histology restrictions, and 491 cancer-free healthy
controls who with no history of cancer, were not receiving
treatment for any diseases, and were frequency-matched to the
cases with respect to age (65 years), gender, ethnicity, and
smoking status (ever or never) were recruited from Zhongnan
Hospital of Wuhan University and Beijing Chaoyang Hospital
between January 2006 and December 2012. Human participant
approval was obtained from the ethical committees of Zhongnan
Hospital of Wuhan University and Beijng Chaoyang Hospital of
Capital Medical University. To avoid confounding due to ethnic
characteristics, we included only Han Chinese in both the case and
control groups. All participants signed written informed consent,
completed a questionnaire regarding demographic and relevant
risk factor information, and donated 3 ml of blood for CHRNA5
genotyping.
CHRNA5 Genotyping
We extracted genomic DNA from a leukocyte cell pellet, which
was obtained from the buffy coat by centrifugation of 1 ml of
whole blood, using the QIAGEN DNA Blood Mini Kit
(QIAGEN, Inc., Valencia, CA, USA) according to the manufac-
turer’s instructions. Agarose gel electrophoresis was used following
amplification using a fluorescence polymerase chain reaction
(PCR). The fluorescence primer sequences for PCR were as
follows: 59-AGCAGACAGGGTTGGACCAGAG-39 (forward);
and 59-CGTGAGACAAAACGAGGGCAGAC-39 (reverse). The
PCR amplification was carried out in a final volume of 20 mL
containing 10 ng of DNA, 1 mM of each primer, 0.3 mM
deoxynucleotide triphosphates (dATP, dCTP, dGTP, and dTTP;
each at 0.3 mM), 3.0 mM MgCl2, 1x HotStarTaq buffer, and 1
unit of HotStarTaq Polymerase (Qiagen, Inc.). The reaction was
started at 95uC for 2 min, followed by 11 cycles of amplification
(94uC for 20 sec, 65uC for 40 sec, and 72uC for 90 sec), 24 cycles
of amplification (94uC for 20 sec, 59uC for 30 sec, and 72uC for
90 sec), extension at 68uC for 60 min, and 4uC until used. The 15-
mL PCR product was added to 5 U SAP enzyme and 2 U
exonuclease at 37uC for 60 min, then 75uC for 15 min. The 0.5-
mL extension product and 0.5-mL fluorescence PCR product were
added to 0.5-mL Lizl 20 SIZE STANDARD and 8.50.5-mL Hi-Di,
incubated at 95uC for 5 min, then scanned using an ABI3730XL
sequenator. Data from the ABI3730XL sequenator was analyzed
using a GeneMapper 4.1 (Applied Biosystems Co., Ltd., USA).
The expected size of the PCR product was 267 base pairs (bp) for
the rs3841324 ins allele and 245 bp for the del allele.
Statistical Analysis
Statistical Analysis System software (version 9.1; SAS Institute,
Cary, NC, USA) was used for all statistical analyses. Ever-smokers
were subjects who had smoked .100 cigarettes in their lifetime,
and the remaining smokers were categorized as never-smokers.
Ever-drinkers were subjects who drank alcoholic beverages at least
once a week for .1 year and the remaining drinkers were
categorized as never drinkers. NPC was classified by the World
Health Organization (WHO) in 1991 into two categories based on
the histologic type, as follows: type I, keratinizing squamous cell
carcinoma; and type II, non-keratinizing carcinoma [19]. The
differences in the distributions of select demographic variables,
smoking status, alcohol consumption, and CHRNA5 rs3841324
allele and genotype frequencies between the cases and controls
were evaluated using a x2 test. The mean values of age were
compared for cases and controls using a Student’s t-test. We
estimated the association between CHRNA5 genotypes and the
risk of NPC by computing the odds ratios (ORs) and 95%
confidence intervals (CIs) by univariate and multivariate logistic
regression analyses. We further stratified the genotype data by
subgroups of age, gender, smoking, alcohol consumption, and
pathology of NPC. For logistic regression analysis, the CHRNA5
genotype was tested with dominant model. We create a dummy
variable to represent CHRNA5 coding wild type as 0, heterozy-
gous and rare allele homozygous as 1. In the multivariate logistic
regression model, the OR and 95% CI were adjusted by age,
gender, smoking, and alcohol consumption. Statistical analyses
Variant on Lung Cancer Risk Locus and Nasopharyngeal Carcinoma
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were performed with Statistical Analysis System softwareand P
values,0.05 were considered significant.
Results
For this study, complete CHRNA5 genotype data, demographic
characteristics, and smoking and alcohol consumption status were
available for 400 cases with NPC and 491 healthy controls
(Table 1). No significant differences in age, gender, or alcohol
consumption status existed between the NPC patients and healthy
controls (P = 0.061 for age, 0.321 for gender, and 0.186 for alcohol
consumption). However, the mean age for the patients with NPC
(49.7611.1) was significantly greater than the controls (47.169.65;
P = 0.0001). Additionally, the distribution of cigarette smoking was
significantly different between cases and controls (P,0.0001), with
smokers being overrepresented among the case group. Conse-
quently, all of these variables were further adjusted for multivariate
regression analysis. We also found significant differences in
rs3841324 between the NPC cases and healthy controls
(P = 0.021).
We also test the genotype distributions and allele frequencies of
CHRNA5 rs3841324 in the NPC cases and cancer-free controls.
The ins and del allele frequencies were in Hardy-Weinberg
equilibrium for both cases and controls (x2 = 0.227, P = 0.634 and
x2 = 3.619, P = 0.057, respectively). The del allele was more
common among the cases (30%) than controls (25.3%), and this
difference was statistically significant (x2 = 5.216, P = 0.022),
implying that the del allele represented a risk factor for NPC.
Similarly, the difference in the CHRNA5 ins/ins, ins/del, and
del/del genotype distributions between the NPC cases and
controls were statistically significant (x2 = 7.762, P = 0.021) and
the ins/del heterozygote was more common among the NPC cases
than among the controls, the difference were statistically
significant (x2 = 7.676, P = 0.006). In contrast, although the del/
del homozygotes were more common among the cases (8.5%) than
controls (8.2%), this difference did not reach statistical significance
(x2 = 0.909, P = 0.340). Compared to the ins/ins homozygotes, the
ins/del heterozygotes were associated with a 55% elevated risk
(adjusted OR = 1.55; 95% CI, 1.17–2.07) for NPC, and the del/
del homozygotes also had an increased risk for NPC, although not
statistically significant (adjusted OR = 1.34; 95% CI, 0.81–2.23).
Furthermore, we found a significant dose-response relationship
between the number of del alleles and the risk of NPC (P = 0.011).
To further evaluate the NPC risk associated with the CHRNA5
polymorphism, we performed stratification analysis by age,
gender, cigarette smoking, alcohol consumption, and pathology.
Because the del/del variant homozygotes were relatively uncom-
mon, we combined the del/del variant homozygotes with the ins/
del variant heterozygotes for this stratification analysis (Table 2).
Compared with the ins/ins genotypes, the combined variant
genotypes (ins/del+del/del) exhibited a .1.5-fold increased risk
for NPC (adjusted OR = 1.52; 95% CI, 1.16–2.00). In addition,
the increased NPC risk associated with the combined variant
genotypes (ins/del+del/del) was evident for ever-smokers (adjusted
OR = 2.07; 95% CI, 1.23–3.48), middle-aged subjects (40–60
years of age; adjusted OR = 1.60; 95% CI, 1.14–2.25), never-
drinkers (adjusted OR = 1.53; 95% CI, 1.11–2.09), males (adjusted
OR = 1.66; 95% CI, 1.19–2.32), or for non-keratinizing carcino-
ma (adjusted OR = 1.52; 95% CI, 1.15–2.00). We also found a
borderline significant interaction between CHRNA5 rs3841324
genotypes and smoking status (P = 0.080), and a significant
interaction between CHRNA5 rs3841324 genotypes and age
(P = 0.002); however, there was no evidence for an interaction
between the CHRNA5 variant genotypes and gender (P = 0.373)
or drinking status (P = 0.510) on the risk of NPC. Furthermore, we
examined the joint effect of the CHRNA5 rs3841324 genotype
and smoking status on the risk of NPC and found that ever-
smokers with the CHRNA5 rs3841324 ins/del or del/del allele
had a .4-fold increased risk for NPC (adjusted OR = 4.35; 95%
Table 1. Frequency Distribution of Demographic and Risk Factors in NPC Cases and Controls.
Variable Cases (No. = 400) Controls (No. = 491) P-value*
No. (%) No. (%)
Age (years)
,40 63 15.8 105 21.4 0.061
40–60 278 69.5 329 67.0
.60 59 14.7 57 11.6
Sex
Male 286 71.5 336 68.4 0.321
Female 114 28.5 155 31.6
Smoking Status
Ever 158 39.5 126 25.7 ,0.0001
Never 242 60.5 365 74.3
Drinking Status
Ever 116 29.0 123 25.1 0.186
Never 284 71.0 368 74.9
CHRNA5 rs3841324
Ins/Ins 194 48.5 283 57.6 0.021
Ins/Del 172 43.0 169 34.4
Del/Del 34 8.5 39 8.0
doi:10.1371/journal.pone.0109036.t001
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CI, 2.57–7.38) compared with non-smokers homozygous for the
ins allele (Table 3).
Discussion
CHRNA5, located at the 15q25.1 lung cancer susceptibility
locus [5], is an attractive candidate gene for smoking behavior,
nicotine dependence, and smoking-related disease, as they have
been plausibly linked with carcinogenesis [20,21]. In this case-
control comparison study, we found a significant association
between CHRNA5 rs3841324 variant genotypes and NPC risk,
and individuals with CHRNA5 rs3841324 combined variant
genotypes (ins/del+del/del) had an elevated risk compared to the
CHRNA5 ins/ins genotype, especially among ever-smokers. In
addition, the combined variant genotypes (ins/del+del/del), in
conjunction with cigarettes smoking, increased NPC risk, thus
indicating that the CHRNA5 rs3841324 variant not only could be
a risk factor and a novel biomarker for prediction of smoking
related NPC risk, but also might be involved in the etiology of
cigarette smoking-mediated cancer. A possible explanation for this
finding is that the 22 bp insertion at the position 271 deletion
upstream of the transcription start site change results in an
alteration of transcription factor binding sites [22] and DNA-
protein interactions [16], and thereby affects the CHRNA5
mRNA level and transcription [15].
It is biologically plausible that genetic variations in the 15q25.1
lung cancer susceptibility locus not only affects risk of smoking-
associated cancers directly, but also acts jointly with smoking
habits for the etiology of NPC. First, the 15q25.1 locus has been
verified to be associated with smoking behavior, persistence, and
nicotine dependence [23], thereby influencing the intensity,
duration, and cumulative consumption of cigarette exposure,
and consequently increases the incidence of smoking-associated
diseases, including smoking-associated cancers. In addition, it is
through the acetylcholine receptor pathway, which was composed
of CHRNA5 and CHRNA3 in the 15q25.1 locus, that nicotine
promote cancer cell proliferation, survival, migration, invasion,
and tumor etiology and development [3]. Therefore, variants in
the 15q25.1 locus have been implicated with nicotine-mediated
cancers.
This is the first molecular epidemiologic study to investigate the
association between CHRNA5 rs3841324, a susceptible variation
for lung cancer, and susceptibility to smoking-associated cancer in
addition to lung cancer. The findings of the current study may
provide novel information on the etiology of smoking-mediated
cancers, verify the role of the 15q25.1 lung cancer susceptibility
locus in the risk of smoking-associated cancers, and elucidate the
carcinogenic mechanisms by which genetic variants at these
regions influence cancer risk. As an oncogenic agent, smoking is
estimated to cause approximately 31% and 6% of all cancer
deaths in men and women worldwide for people between 30 and
69 years, respectively [2]. These types of cancers include lung
cancer [24], NPC [4], oral cavity cancer [25], esophageal cancer
[26], colorectal cancer [27], invasive cervical cancer [28], skin
cancer [29], prostate cancer [30], kidney cancer [31], breast
cancer [32], bladder cancer [33], and pancreatic cancer [34].
Evaluation of the impact of genetic variants on smoking-related
disease, especially on smoking-mediated cancers, is of value to
public health [20,35].
Several GWAS have demonstrated that genetic variants in
CHRNA5 and CHRNA3, located at the 15q25.1 lung cancer
susceptibility locus [20,21], influence the risk of developing lung
cancer in European and US populations [5,21]. Since then, three
studies have examined the associations between the CHRNA5
rs3841324 variant and lung cancer risk, with inconsistent results
[6,16,36]. For example, Amos et al. (6) found that in ever-smokers,
homozygous carriers of del variants of rs3841324 exhibited a
decreased lung cancer risk in females, but had little effect in males
in 624 lung cancer patients and 766 healthy controls from a
Caucasian population. A study explored the association between
the CHRNA5 rs3841324 polymorphism and lung cancer risk in a
Han Chinese population and found no significant association, but
revealed that 2 least frequent haplotypes, rs3841324 ins/
rs3829787 T and rs3841324 del/rs3829787 C were statistically
decrease lung cancer risk [16]. Recently, another study with a
Caucasian population of Norwegian origin also showed that
rs3841324 statistically influenced the risk of developing lung
cancer and a significantly reduced risk of developing non-small-cell
lung cancer exists for del allele homozygotes, especially lung
tumors harboring a mutated TP53 [36].
Interestingly, in our studies, CHRNA5 rs3841324 combined
variant genotypes (ins/del+del/del) had an increased NPC risk
compared to ins allele homozygotes, which is inconsistent with the
results for lung cancer in which the del allele was a protective
factor for a Caucasian population [6,36]. The discrepancy may
result from different tumor sites and ethnicities studied. Previous
studies have demonstrated that del allele homozygotes at
rs3841324 have a 2.9-fold increase in CHRNA5 mRNA levels
in the frontal cortex and that low levels of CHRNA5 mRNA are
associated with a lower risk for nicotine dependence and lung
cancer [15]. Therefore, del allele homozygotes at rs3841324 are
more likely to be at increased risk for nicotine dependence and
smoking persistence with increased CHRNA5 mRNA levels in the
frontal cortex, and is consequently more likely to be associated
with a higher incidence of smoking-mediated cancers. In addition,
a study [16] conducted in a Han Chinese population showed no
significant association between CHRNA5 rs3841324 variants and
lung cancer risk in contrast with the reports conducted in a













No. (%) No. (%)
Never Ins/Ins 115 (36.9) 197 (63.1) 1.00 1.00
Never Ins/Del + Del/Del 127 (43.1) 168 (56.9) 1.30 (0.94–1.79) 1.33 (0.95–1.85)
Ever Ins/Ins 79 (47.9) 86 (52.1) 1.57 (1.07–2.31) 1.47 (0.95–2.27)
Ever Ins/Del + Del/Del 79 (66.4) 40 (33.6) 3.38 (2.17–5.28) 4.35 (2.57–7.38)
aadjusted for age, sex, smoking and alcohol accordingly.
doi:10.1371/journal.pone.0109036.t003
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Caucasian population [6,36], which suggested the effect of various
ethnicities studied. Other studies have demonstrated that variants
at the 15q25.1 locus, including rs3841324, may contribute
differently to nicotine dependence [37] and cigarette use [38] in
European-Americans and African-Americans, which also verifies
the effect of diverse ethnicities. Finally, the role of rs3841324 in the
etiology of the smoking related cancers has not been confirmed in
basic biologic research and rs3841324 might just be a marker in
linkage disequilibrium with different causal variants in various
smoking related cancers, which also might contribute to the
discrepancy in the direction of association. These hypotheses,
however, need to be confirmed in future studies.
The current study is the first to report the combined effect of
exposure to cigarette smoke and genetic variants at the 15q25.1
lung cancer susceptibility locus on the risk of smoking-mediated
cancer. Smokers who had ins/del or del/del genotypes were .4-
fold more likely to develop NPC than non-smokers homozygous
for the insertion allele, which was much higher than the effect of
smoking exposure or genetic variants at the 15q25.1 lung cancer
susceptibility locus alone. This findings suggest that genetic
variants at the 15q25.1 lung cancer susceptibility locus is an
independent risk factor influencing inheritance susceptibility and is
also plausible to be a cofactor of cigarettes. Genetic susceptibility
and environmental exposure for NPC risk has been widely verified
in various populations [39]. However, few case-control compar-
ison studies have investigated the interaction of hereditary
predispositions and smoking exposure in the etiology of NPC.
Nevertheless, there are three facts which support our findings.
First, the biologic mechanism underlying how cigarettes and genes
interact at the 15q25.1 lung cancer susceptibility locus is somewhat
clear. The fact that tobacco alkaloid and nicotine can bind and
activate the nicotinic acetylcholine receptors, and thereby
stimulate cellular proliferation and tumor invasion, and inhibit
apoptosis [9–11], might partly explain the synergism between
exposure to cigarette smoking and the 15q25.1 locus on the
etiology of NPC. Second, variants at the 15q25.1 lung cancer
susceptibility locus could have an effect on smoking persistence
[12], smoking behavior, and nicotine dependence [13]. Finally,
studies in bladder cancer [40], lung cancer [41], and NPC [4]
have demonstrated the combined effect of exposure to cigarette
smoking and heredity also partly support our findings.
Another important finding in our study was that the risk of NPC
associated with rs3841324 genotypes harboring del alleles was
significantly higher for males. The plausible explanation for this
observation might be attributed to males being more strongly
associated with cigarette smoking. A much higher proportion of
males smoke cigarettes and have smoking-associated cancer deaths
than females worldwide [2]. In the current study, the increased
NPC risk associated with genetic variation at the 15q25.1 locus in
ever-drinkers was nearly equal to never-drinkers. We speculate
that the discrepancy is partly attributed to the sample sizes in the
ever- and never-drinkers because NPC risk was not associated with
alcohol consumption [4].
Although conducted in a large, well-characterized case-control
comparison, our study had several limitations. First, possible
limitations in our hospital-based case-control study design could
have introduced some selection bias because subjects were not
from the same population. However, all of the subjects were Han
Chinese and both areas in which the hospitals were located are low
NPC risk regions in China. In addition, we have found that the
frequency of the CHRNA5 genotypes in cases and controls
between the two hospitals was not statistically different, and the
frequency of the CHRNA5 genotypes in the healthy control group
in the current study was similar to those in previous reports with
Han Chinese subjects [16]. Second, the number of observations in
some strata of the stratification analysis was relatively small;
however, after adjustment for age, gender, cigarette smoking, and
alcohol consumption the potential impact from confounding
factors on ORs might be minimized. Another possible source of
bias in our study might result from the bias of self-reported
exposure histories, including histories of cigarette smoking and
alcohol consumption. To confirm the role of genetic variants on
the 15q25.1 lung cancer susceptibility locus in smoking-associated
cancers and whether or not it could be a biomarker for
identification of smoking-associated cancers, further studies should
be investigated with larger sample sizes in different populations
involving other anatomic sites of cancers.
In conclusion, our study demonstrated that genetic variants of
the 15q25.1 lung cancer susceptibility locus, rs3841324, are
significantly associated with NPC, a smoking-associated cancer
other than lung cancer. This observation was especially pertinent
to smokers, and could act jointly with cigarette smoking to increase
NPC risk, indicating that this genetic variation can serve as a
biomarker for the early identification of at-risk populations for
smoking-associated cancers. We also noted that the association
was most evident in males. This is the first time the role of genetic
variants at the 15q25.1 lung cancer susceptibility locus and NPC
risk has been examined, which is of value. Further validation of
our findings by larger studies and exploration of the underlying
molecular mechanisms are warranted.
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